The real world data (RWD) and real world evidence (RWE) landscape continues to evolve rapidly and pharmaceutical companies are increasingly moving from multiple one-off secondary data studies towards a standing, multipurpose evidence infrastructure. As adoption expands, evidence platforms will be integral to ongoing product success, providing continuous, high-quality, real-time data and insights to all critical stakeholders: physicians, payers and regulators. A single source of evidence truth will become the basis for multi-stakeholder engagement and collaboration, improving the quality and efficiency of healthcare delivery.
In this paper, discover more about: